Format

Send to

Choose Destination
Pharm Res. 1998 Mar;15(3):423-8.

Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers.

Author information

1
Preclinical Research Department, F. Hoffman-La Roche Ltd, Basel, Switzerland.

Erratum in

  • Pharm Res 1998 Jun;15(6):958.

Abstract

PURPOSE:

To investigate in vitro the mechanisms involved in the gastro-intestinal absorption of the HIV protease inhibitor, saquinavir mesylate (Invirase), whose oral bioavailability is low, variable, and significantly increased by co-administration with ritonavir, also an HIV protease inhibitor but with higher oral bioavailability.

METHODS:

Confluent epithelial layers of human Caco-2 cells mimicking the intestinal barrier.

RESULTS:

Both saquinavir and ritonavir showed polarized transport through Caco-2 cell monolayers in the basolateral to apical direction (secretory pathway), exceeding apical to basolateral transport (absorptive pathway) by factors of 50-70 and 15-25, respectively. Active efflux was temperature dependent, saturable and inhibited by verapamil and cyclosporin A. Saquinavir and ritonavir decreased each other's secretory permeability and hence elevated their net transport by the absorptive pathway.

CONCLUSIONS:

Saquinavir and ritonavir are both substrates for an efflux mechanism in the gut, most likely P-glycoprotein, which acts as a counter-transporter for both drugs. Together with sensitivity to gutwall metabolism by cytochrome P-450 3A, this may partially account for the low and variable oral bioavailability of saquinavir in clinical studies and for its increased bioavailability after co-administration with ritonavir.

PMID:
9563072
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center